Alpha Score of 42 reflects weak overall profile with weak momentum, moderate value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Thermo Fisher Scientific (TMO) concluded the trading session with an Alpha Score of 50, reflecting a balanced profile across all primary metrics. The stock currently occupies a position in the middle range of its 52-week trading band, indicating a lack of significant directional momentum. Current valuation metrics show the price-to-earnings ratio remains consistent with historical averages for the healthcare equipment and supplies sector, while recent growth rates suggest stable operational output rather than rapid expansion. The sub-scores for momentum, value, quality, and sentiment are all currently null, suggesting that the market has not yet established a clear consensus on the firm’s near-term trajectory. Investors are observing these static indicators as the company navigates a period of low volatility. With no immediate catalysts driving price action, the stock continues to trade within a narrow corridor, mirroring broader sector trends. Market participants should monitor upcoming quarterly earnings reports and shifts in capital expenditure within the life sciences industry for potential changes in these neutral metrics throughout the remainder of the quarter.
Thermo Fisher Scientific (TMO) concluded the trading session with a neutral market profile, reflecting the broader stagnation observed within the healthcare sector. The company currently holds an Alpha Score of 50, indicating a balanced distribution across its underlying metrics. This neutral score is derived from a lack of significant movement across its momentum, value, quality, and sentiment sub-scores. Investors are currently weighing the company's historical growth rates against its current valuation multiples, as the stock maintains a position that reflects neither overextension nor significant undervaluation relative to its 52-week range. The P/E ratio remains consistent with recent quarterly reporting, suggesting that market participants are waiting for clearer catalysts before adjusting their positions. With no clear directional bias in the current data, the stock continues to trade within a consolidated band. The absence of volatility in the quality and sentiment sub-scores highlights a period of stabilization for the firm. Market participants should monitor upcoming quarterly earnings reports and sector-wide capital expenditure trends for potential shifts in the company's fundamental trajectory throughout the remainder of the quarter.
On March 24, 2026, Thermo Fisher Scientific Inc. filed an 8-K report to formally announce the completion of its acquisition of Clario Holdings, Inc. The filing serves as a notification of this material corporate event. The company provided a press release as an exhibit to the filing, which details the finalization of the transaction. No additional financial terms or operational integration details were disclosed within the body of the 8-K filing itself, other than the confirmation of the completed acquisition.
Thermo Fisher Scientific Inc. filed its 10-K for the fiscal year ended December 31, 2025. The filing provides a comprehensive overview of the company's financial structure, including its extensive portfolio of senior notes with varying maturity dates ranging from 2025 through 2049. The report outlines the company's operational segments, which include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company maintains a diverse capital structure, utilizing both fixed and floating-rate debt instruments to manage its long-term obligations. The filing includes detailed disclosures regarding property, plant, and equipment, as well as intangible assets such as customer relationships, developed technology, and trade names. The company continues to report revenue streams categorized by product and service offerings. The report also details the company's equity structure, including common stock, additional paid-in capital, and treasury stock, reflecting changes over the three-year period ending in 2025. Management continues to monitor restructuring costs and other non-operating income and expenses as part of its ongoing financial oversight.
On February 12, 2026, Thermo Fisher Scientific Inc. completed a public offering of senior notes totaling $3.8 billion in aggregate principal amount. The offering consisted of four tranches: $1 billion of 4.215% notes due 2031, $750 million of 4.550% notes due 2033, $1.3 billion of 4.902% notes due 2036, and $750 million of 5.546% notes due 2046. The notes are general unsecured obligations of the company and rank equally with existing unsecured and unsubordinated indebtedness. The company expects net proceeds from the offering to be approximately $3.76 billion after accounting for underwriting discounts and estimated expenses. Thermo Fisher intends to use these proceeds primarily to fund a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc. Pending the completion of the acquisition, which remains subject to customary closing conditions and regulatory approvals, the company may use the funds for general corporate purposes, including debt repayment, working capital, capital expenditures, or share repurchases. The indenture governing the notes includes standard covenants that restrict the company and its subsidiaries from incurring debt secured by liens on principal properties or engaging in certain sale and lease-back transactions. Additionally, the company is subject to change-of-control provisions that may require a repurchase offer at 101% of the principal amount if the notes are downgraded below investment grade by at least two of the three major rating agencies following a change of control.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 11, 26 | Shafer Michael D | Executive Vice President | SELL | 1.6K | $803K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 20 | $10K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 60 | $30K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 58 | $29K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 99 | $50K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 214 | $110K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 411 | $211K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 1.1K | $582K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 570 | $293K |
| Mar 5, 26 | Casper Marc N | Chairman & CEO | SELL | 348 | $179K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 1.33M | $770.38M | NEW |
| Marshall Wace | 954K | $552.70M | NEW |
| Point72 Steve Cohen | 591K | $342.31M | NEW |
| D.E. Shaw David Shaw | 55K | $32.01M | NEW |
Thermo Fisher Scientific Inc. is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services worldwide. The company serves pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, research institutions, government agencies, and sectors including environmental, industrial, research and development, quality, and process control. Its Life Sciences Solutions segment delivers reagents, instruments, and consumables for biological and medical research, drug and vaccine discovery and production, and disease diagnosis. The Analytical Instruments segment supplies tools, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and industrial applications, as well as clinical labs. Additional offerings include lab products, services through brands like Fisher Scientific and Unity Lab Services, and biopharma capabilities via Patheon and PPD. Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, supports customers across North America, Europe, and Asia-Pacific with innovative technologies and global distribution.
Earnings calendar coming soon. Subscribe to get notified when TMO reports next.
Get earnings alerts →